Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on INCYTE CORPORATION
08/17 INCYTE : Forbes Magazine Names Incyte One of the World's Most Innovative Compani..
08/16 INCYTE : Scientist Behind Incyte's Jakafi Ready to Strike Big in Delaware Again
08/15 INCYTE : founder gets $474K from Delaware to fund new cancer drug company Prelud..
08/10 INCYTE : Forbes Magazine Names Incyte One of the World’s Most Innovative C..
08/09 Calithera Biosciences Reports Second Quarter 2017 Financial Results and Recen..
08/08 INSIDER TRADING ACTIVITY INCYTE CORP : INCY) – Insider Sold 3,000 shares o..
08/03 INCYTE : New Pharmacokinetics Data Have Been Reported by Investigators at Incyte..
08/03 ELI LILLY AND : Lilly and Incyte Provide Update on Baricitinib
08/02 INCYTE : posts loss for quarter, but sees strong sales for blockbuster drug Jaka..
08/01 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
08/01 INCYTE CORPORATION (NASDAQ : INCY) reported earnings of ($0.06) per share missin..
08/01 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
08/01 INCYTE : reports 2Q loss
08/01 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
08/01 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
08/01 INCYTE : Reports 2017 Second-Quarter Financial Results and Updates on Key Clinic..
07/29 REGENERON PHARMACEUTICALS : U.S. Court of Appeals for the Federal Circuit Affirm..
07/27 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/27INCYTE CORPORATION : half-yearly earnings release
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/22 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/21 INSIDER TRADING ACTIVITY INCYTE CORP : INCY) – EVP Sold 6,485 shares of St..
07/20 INCYTE : Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib..
07/13 ELI LILLY AND : Japan Ministry of Health, Labor and Welfare MHLW Grants Marketin..
07/11 INCYTE : to Report Second Quarter Financial Results
07/06 INCYTE : Lillys Olumiant, spurned by FDA, gets nod from NICE
07/05 NETWORKNEWSBREAKS – AEGIS CAPI : Cnce)
07/05 INCYTE : & Lilly`s Olumiant Gets Marketing Approval in Japan
07/03 INCYTE : Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing App..
06/22 ELI LILLY AND : New Safety and Long-Term Efficacy Data from Baricitinib Clinical..
06/20 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/20 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/16 INCYTE : New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials..
06/15 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/15 INCYTE : Updated Data from ECHO-202 Trial of Incyte's Epacadostat in Combination..
06/14 INCYTE : Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arth..
06/09 INCYTE : Researchers at Incyte Corporation Report New Data on Medicinal Chemistr..
06/07 INCYTE : to Present at Upcoming Investor Conferences
06/06 INCYTE CORPORATION : Corporate News Blog - Incyte and Merck Release Phase-1/2 Cl..
06/05 INCYTE : Analyst and Investor Event to Highlight Clinical Data Presentations fro..
06/05 INCYTE : Updated Data from ECHO-202 Trial of Epacadostat in Combination with KEY..
06/04 INCYTE : Merck early-stage study of cancer drug combo shows promise
06/03 INCYTE : Combination of Epacadostat plus Keytruda® (pembrolizumab) Demonstrates ..
05/30 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Submission of Matters to a Vote ..
05/25 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/25 INCYTE : First Data from Combination of Epacadostat with Opdivo® nivolumab Will ..
05/22 INCYTE : to Present at Upcoming Investor Conferences
05/18 INCYTE : Vaults on Drug Test Results
05/18 S&P 500 MOVERS : Csco, incy
05/18 NASDAQ 100 MOVERS : Csco, incy
05/17 INCYTE : First Data from Combination of Epacadostat with Opdivo® (nivolumab) Wil..
05/17 INCYTE : New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Ep..
05/04 INCYTE : Management's Discussion and Analysis of Financial Condition and Results..
05/04 INCYTE : reports 1Q loss
05/04 INCYTE CORP : Results of Operations and Financial Condition, Financial Statement..
05/04 INCYTE CORPORATION : Investor Network: Incyte Corporation to Host Earnings Call
05/04 INCYTE CORPORATION (NASDAQ : INCY) Files An 8-K Results of Operations and Financ..
05/04 INCYTE : Reports 2017 First-Quarter Financial Results and Updates on Key Clinica..
05/04 INCYTE : reports strong revenue growth, loss for 1st quarter
04/25 INCYTE : to Present at Upcoming Investor Conferences
04/21 NASDAQ 100 MOVERS : Mat, incy
04/20 INCYTE : Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured ..
04/20 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporat..
04/19 Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corpo..
04/18 INCYTE : to Report First Quarter Financial Results
04/18 INCYTE : FDA stuns Lilly and Incyte with CRL for much-anticipated RA drug barici..
04/18 Lilly and Incyte`s Loss Is AbbVie and Regeneron`s Gain
04/17 INCYTE CORPORATION : (INCY) Slides on FDA Nod
04/17 INCYTE CORP : Other Events (form 8-K)
04/15 ELI LILLY AND : Incyte Say FDA Issues CRL For Baricitinib
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
04/03 INCYTE : and Merck Provide Additional Details on Previously Announced Collaborat..
04/03 S&P 500 MOVERS : Hpe, incy
04/01 INCYTE : INCY) and Merck (MRK) Amplify Anti-tumor Collaboration
1  2  3  4  5  6  7Next
Financials ($)
Sales 2017 1 468 M
EBIT 2017 -71,1 M
Net income 2017 -168 M
Finance 2017 340 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 299,53
EV / Sales 2017 16,7x
EV / Sales 2018 14,5x
Capitalization 24 929 M
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 148 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Michael Morrissey Senior VP & Head-Global Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION20.86%24 929
QUINTILES IMS HOLDINGS INC20.38%19 823
LONZA GROUP42.86%17 682
CELLTRION, INC.--.--%11 804
ALKERMES PLC-8.38%7 821
ALNYLAM PHARMACEUTICALS, INC.114.42%7 469